1. Report of a unique case of gemcitabine-induced radiation recall myelitis following spinal cord irradiation
- Author
-
Stéphane Supiot, Isabelle Doutriaux-Dumoulin, F. Thillays, and Ingrid Masson
- Subjects
Chemotherapy ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Myelitis ,Case Report ,Context (language use) ,General Medicine ,Spinal cord ,medicine.disease ,Radiation recall ,Gemcitabine ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Medicine ,Irradiation ,Radiology ,business ,Lung cancer ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Radiation recall is a rare phenomenon, defined as an acute inflammatory reaction in a previously irradiated area, after administration of anti-tumor agents, including chemotherapy. It is most commonly reported to trigger skin reactions but internal organ involvement is possible, particularly with gemcitabine. We report here a unique case of a gemcitabine-induced radiation recall myelitis following spinal irradiation. A 53-year-old patient received analgesic irradiation of the seventh thoracic vertebra (T7) in the context of metastatic non-small cell lung cancer, at conventional radiotherapy dose and fractionation. She was subsequently treated with gemcitabine and developed myelitis whose chronology is compatible with a radiation recall reaction. Spinal MRI confirmed a T6–T7 spinal cord enhancement, with an associated spinal cord oedema. Corticosteroids and supportive care did not improve myelitis symptoms. The patient died within a year of the radiation recall, due to a metastatic progression of lung cancer. This is, to our knowledge, the first reported case of gemcitabine-induced radiation recall myelitis and only the third case involving the spinal cord. Radiation recall is a rare and poorly understood phenomenon and all cases should be reported.
- Published
- 2020
- Full Text
- View/download PDF